Anaconda Biomed Appoints Trent Reutiman New CEO
3 days ago · Reutiman brings more than twenty-five years of executive, financial, market development, and sales operation leadership experience to Anaconda, with an extensive focus in vascular technologies.
Anaconda Biomed Appoints Trent Reutiman New CEO
1 day ago · Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has named long-time medtech executive Trent Reutiman as its new CEO. Based in California’s San Francisco Bay Area, Reutiman will establish a new footprint for the company in the U.S. as it works towards regulatory approval of its ANA5 ...
Anaconda Biomed Appoints Trent Reutiman New CEO - Yahoo …
2 days ago · Seasoned Medtech Executive to Expand Company Presence Into U.S. BARCELONA, Spain & MARIN, Calif., January 07, 2025--(BUSINESS WIRE)--Anaconda Biomed S.L., a medical technology company developing ...
Anaconda Biomed Appoints Trent Reutiman New CEO
3 days ago · Seasoned Medtech Executive to Expand Company Presence Into U.S. BARCELONA, Spain & MARIN, Calif.–(BUSINESS WIRE)– Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has named long-time medtech executive Trent Reutiman as its new CEO. Based in California’s San Francisco Bay Area ...
Anaconda Biomed Appoints Trent Reutiman as CEO
3 days ago · January 7, 2025—Anaconda Biomed S.L. announced that it named Trent Reutiman its new CEO. The company’s previous CEO Francois Salmon will now serve as Anaconda’s Board Chairman. Anaconda, a developer of thrombectomy systems for treating ischemic stroke is headquartered in Barcelona, Spain ...
Anaconda Biomed appoints Trent Reutiman as new CEO
1 day ago · Anaconda Biomed has announced that it has named long-time medtech executive Trent Reutiman as its new chief executive officer (CEO). A press release details that, based in California’s San Francisco Bay Area, Reutiman will establish a “new footprint” for the company in the USA as it works towards regulatory approval of its ANA5 advanced neurovascular access—a catheter-based […]
Anaconda Biomed Appoints Trent Reutiman New CEO
2 days ago · Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has named long-time medtech executive ...
Trent Reutiman Named New CEO of Anaconda Biomed
3 days ago · Reutiman will help expand the company into the U.S. Continue to Medical Product Outsourcing. Magazine. Latest Issues. ... Subscribe to MPO Magazine for the latest news and updates delivered straight to your mailbox. View all ; Supply Chain. 3D/Additive Manufacturing. 3D/Additive Manufacturing.
Data from First Phase of DEXTERITY-AFP Study Unveiled at VEINS …
Dexter, on behalf of the DEXTERITY-AFP study investigators, presented compelling findings that have the potential to reshape deep vein thrombosis (DVT) therapy in patients who have exhibited symptoms for less than 14 days (the acute phase). Dr.
Mercator MedSystems to study its Bullfrog micro-infusion device …
Nov 6, 2017 · “This technology is so hyper-efficient,” CEO Trent Reutiman told Drug Delivery Business News. “It delivers the drug very locally and precisely to the tissue surrounding a blood vessel or an airway.” The 16-person company has used its device in above-the-knee applications and is now applying Bullfrog for below-the-knee lesions.
- Some results have been removed